Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy. READ MORE

News

Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy.

READ MORE

An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.

READ MORE

Research in Review

A recent comparative effectiveness study examined the relationship of ACPA status and accrued economic burden for patients with rheumatoid arthritis.

READ MORE

Recent research suggests that 40% of older patients with rheumatoid arthritis still take opioids regularly as of 2014.

READ MORE

Researchers developed a method of identifying candidates for dose reduction of disease modifying anti-rheumatic drugs.

READ MORE

A cost-effectiveness analysis showed that patients with RA who switch from an antirheumatic drug to a biologic drug are likely to increase costs of care.

READ MORE